218 related articles for article (PubMed ID: 34433584)
1. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB; Meza-Perez S; Londoño A; Katre A; Peabody JE; Smith HJ; Forero A; Norian LA; Straughn JM; Buchsbaum DJ; Randall TD; Arend RC
Oncotarget; 2017 Jul; 8(27):44159-44170. PubMed ID: 28498806
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Stone ML; Chiappinelli KB; Li H; Murphy LM; Travers ME; Topper MJ; Mathios D; Lim M; Shih IM; Wang TL; Hung CF; Bhargava V; Wiehagen KR; Cowley GS; Bachman KE; Strick R; Strissel PL; Baylin SB; Zahnow CA
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10981-E10990. PubMed ID: 29203668
[TBL] [Abstract][Full Text] [Related]
4. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
5. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
Scotto L; Kinahan C; Douglass E; Deng C; Safari M; Casadei B; Marchi E; Lue JK; Montanari F; Falchi L; Qiao C; Renu N; Bates SE; Califano A; O'Connor OA
Mol Cancer Ther; 2021 Aug; 20(8):1422-1430. PubMed ID: 34108263
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
[TBL] [Abstract][Full Text] [Related]
7. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
9. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S; Cox OL; Walker RR; Rentia U; Hadley M; Arthofer E; Diab N; Grundy EE; Kanholm T; McDonald JI; Kobyra J; Palmer E; Noonepalle S; Villagra A; Leitenberg D; Bollard CM; Saunthararajah Y; Chiappinelli KB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36343976
[TBL] [Abstract][Full Text] [Related]
13. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
16. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
20. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
